A gene transfer approach to treating the bleeding disorder hemophilia B remains safe and effective long-term, as scientists ...

Gene therapy has proved to be a safe long-term treatment for haemophilia B. The benefits of a single dose persist for at ...

It was found that those with severe hemophilia B have less than 1% of normal factor IX activity, often experiencing spontaneous bleeding that can cause joint damage or life-threatening events.

In a 13-year follow-up by St. Jude Children’s Research Hospital and University College London published in The New England ...

A UK man became the first NHS patient to receive a multimillion pound wonder drug, Hemgenix, to help treat the clotting ...

In a major breakthrough, UK-based researchers have found that a one-time gene therapy approach for haemophilia B remains safe ...

According to a new study in Haemophilia, up to 60% of patients with severe HA have no known family history, making early ...

The purpose of this gene therapy is for those people living with haemophilia B, once treated, to be able to produce FIX via the treatment (a one-time treatment), rather than having to receive ...

CSL and uniQure’s gene therapy for haemophilia B has been approved by the European Commission, ushering in a new era of therapy for patients with the bleeding disorder in the EU. The therapy has ...

CSL Behring has added another major European market to the list of those providing reimbursement coverage of its haemophilia B gene therapy Hemgenix, after agreeing an access deal in Germany.